(NASDAQ: JANX) Janux Therapeutics's forecast annual revenue growth rate of 145.12% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 82.88%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.63%.
Janux Therapeutics's revenue in 2025 is $9,336,000.On average, 2 Wall Street analysts forecast JANX's revenue for 2025 to be $591,751,570, with the lowest JANX revenue forecast at $591,751,570, and the highest JANX revenue forecast at $591,751,570. On average, 1 Wall Street analysts forecast JANX's revenue for 2027 to be $1,990,652,281, with the lowest JANX revenue forecast at $1,990,652,281, and the highest JANX revenue forecast at $1,990,652,281.
In 2028, JANX is forecast to generate $8,487,788,644 in revenue, with the lowest revenue forecast at $6,348,310,843 and the highest revenue forecast at $12,088,892,824.